Skip to content

Effect of ambroxol inhalation on clinical outcomes and catheter microecology in neonates with ventilator associated pneumonia

Effect of ambroxol inhalation on clinical outcomes and catheter microecology in neonates with ventilator associated pneumonia:A randomized controlled trial

Status
Recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR-IPR-17013279
Enrollment
Unknown
Registered
2017-11-07
Start date
2017-10-27
Completion date
Unknown
Last updated
2017-11-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

neonatal catheter-related infection

Interventions

HA group:Inhalation of 7.5mg/ml ambroxol 2ml under endotracheal intubation, two times a day (with routine combined treatment and care)
NS group:Inhalation of 2ml normal saline under endotracheal intubation, two times a day (with routine treatment and care)
blank group:routine treatment and care only

Sponsors

Children's Hospital of Chongqing Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
No minimum to 1 Years

Inclusion criteria

Inclusion criteria: 1. The patient was admitted to NICU within 24 hours after birth and was intubated for the first time using a constant frequency ventilator; 2. Premature infants diagnosed with respiratory distress syndrome (NRDS) for the first time; 3. The family members shall sign the informed consent; 4. Choose the three generation cephalosporin antibiotics (because the pathogens are mainly gram negative bacteria).

Exclusion criteria

Exclusion criteria: 1. Sepsis, bronchopulmonary dysplasia, tracheoesophageal fistula, congenital heart disease, premature rupture of membranes, severe intracranial hemorrhage, and coagulation disorders; 2. Serious infection;] 3. Use antibiotics before the hospital; 4. The family refused to sign the informed consent.

Design outcomes

Primary

MeasureTime frame
The incidence of ventilator-associated pneumonia;Duration of mechnical ventilation;The positive rate of sputum culture;classification of bacteria;

Secondary

MeasureTime frame
Days of using antibiotics;Use of pulmonary surfactant;days of stay;

Countries

China

Contacts

Public ContactXianhong Zhang

Children's Hospital of Chongqing Medical University

2251867562@qq.com+86 13594681201

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026